PPV23 vaccine is effective against pneumococcal disease in the elderly
Access to the full content of this site is available only to registered healthcare professionals.
Register to read more
The 23-valent pnsumococcal polysaccharide vaccine (PPV23; Prevnar) is effective against invasive pneumococcal disease (IPD) and pneumoccal pneumonia in the elderly, according to a meta-analysis.
Why this matters
High rates of hospitalizations and mortality are observed in the 20-30% of cases of community-acquired pneumonia caused by pneumococcus.
17 clinical trials, cohort studies and case-control studies met eligibility criteria after search of MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews.